Top 5 Extreme Value Stocks To Buy Now

4. Viatris Inc. (NASDAQ:VTRS)

Number of Hedge Fund Holders: 60

On July 1, Viatris Inc. (NASDAQ:VTRS) entered into a loan agreement with a group of lenders led by Mizuho Bank. The company secured a ¥40 billion senior unsecured term loan. This will support general business purposes and also refinance an existing loan of the same amount. The loan carries an interest rate based on the TIBO rate plus 1.10% and will mature in three years. The agreement is backed by guarantees from key subsidiaries of Viatris and includes financial conditions, such as limits on borrowing, dividend payments, and mergers. Moreover, the loan’s pricing and conditions are tied to VTRS’s credit ratings. This encourages the healthcare company to maintain healthy, investment-grade financial metrics.

Earlier on June 29, Viatris Inc. (NASDAQ:VTRS) reported positive phase 3 results for Nefecon in primary immunoglobulin A nephropathy. The company said that it met primary and secondary endpoints in a Japanese trial. In the open-label study, patients taking Nefecon, also known as VR-205, showed a reduction in urine protein levels over time. After nine months, the urine protein-to-creatinine ratio fell by about 33.75% compared to baseline. The drug is approved in the US under the name Tarpeyo and marketed by Calliditas Therapeutics.

Viatris Inc. (NASDAQ:VTRS) operates as a healthcare company. It operates in four segments. These include Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.